Skip to main content

Table 1 Characteristics of PCa patients by T2E-fusion status

From: Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors

 

T2E-negative PCa (n = 230)

T2E-positive PCa (n = 266)

 

Variables

No.

%

Mean (SD)

No.

%

Mean (SD)

P valuea

Age at diagnosis (years)

59.5 (7.1)

56.8 (6.8)

<0.01

Race

      

<0.01

 African-American

29

12.6

14

5.3

 European-American

201

87.4

252

94.7

Gleason score

      

<0.01

 ≤6

92

40.0

141

53.0

 7 (3 + 4)

89

38.7

93

35.0

 7 (4 + 3)

29

12.6

15

5.6

 ≥8

20

8.7

17

6.4

Pathological stage

      

0.70

 Local (pT1/pT2)

159

69.1

179

67.3

 Regional (pT3)

71

30.9

87

32.7

PSA (ng/mL) at diagnosis

      

0.06

 <4

26

12.0

52

20.6

 4– < 10

138

63.6

156

61.9

 10– < 20

38

17.5

28

11.1

 ≥20

15

6.9

16

6.3

  1. T2E TMPRSS2:ERG, PCa prostate cancer, SD standard deviation, PSA prostate-specific antigen
  2. aA t test (age at diagnosis) or chi-square test (all categorical variables) was used